| Literature DB >> 31390787 |
Antonio Francioso1,2,3, Katrin Franke4, Claudio Villani5, Luciana Mosca6, Maria D'Erme6, Stefan Frischbutter7,8, Wolfgang Brandt4, Angel Sanchez-Lamar9, Ludger Wessjohann10.
Abstract
Phyllanthus orbicularis (Phyllanthaceae) is an endemic evergreen tropical plant of Cuba that grows in the western part of the island and is used in traditional medicine as an infusion. The aqueous extract of this plant presents a wide range of pharmacological activitiessuch as antimutagenic, antioxidant and antiviral effects. Given the many beneficial effects and the great interest in the development of new pharmacological products from natural sources, the aim of this work was to investigate the phytochemistry of this species and to elucidate the structure of the main bioactive principles. Besides the presence of several known polyphenols, the major constituent was hitherto not described. The chemical structure of this compound, here named Fideloside, was elucidated by means of HR-ESIMS/MSn, 1D/2D NMR, FT-IR, and ECD as (2R,3R)-(-)-3',4',5,7-tetrahydroxydihydroflavonol-8-C-β-D-glucopyranoside. The compound, as well as the plant aqueous preparations, showed promising bioactive properties, i.e., anti-inflammatory capacity in human explanted monocytes, corroborating future pharmacological use for this new natural C-glycosyl flavanonol.Entities:
Keywords: C-glycoside; Cuba; Fideloside; NMR; Phyllanthus chamacristoides; Phyllanthus orbicularis; anti-inflammatory activity; chromatography; circular dichroism; cytokines; flavonoid; mass spectrometry; natural products; stereochemistry; traditional medicine
Mesh:
Substances:
Year: 2019 PMID: 31390787 PMCID: PMC6695706 DOI: 10.3390/molecules24152855
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1UPLC-DAD (280 nm) chromatograms of Phyllanthus orbicularis and Phyllanthus chamacristoides aqueous extracts and assignments of eluting peaks.
Spectroscopic and spectrometric data of identified compounds.
| Peak | Retention Time (min) | Compound | Molecular Formula | MS1 [M − H]−( | MS2 [M − H]−( | MS3[M − H]−( | |
|---|---|---|---|---|---|---|---|
|
| 3.49 | Protocatechuic acid glucoside | C13H16O9 | 290 | 315.0717 | 153.0196 | 109 |
|
| 3.52 | C15H16O10 | 326 | 355.0668 | 191.0198 | 147; 85 | |
|
|
|
|
|
|
|
|
|
| 3.85 | Catechin | C15H14O6 | 278 | 289.0720 | 271.0620; 245.0825 | ||
| 4.07 | Procyanidin B2 | C30H26O12 | 280 | 577.1352 | 451.1036; 425.088; 289.0720 | ||
| 4.23 | Epicatechin | C15H14O6 | 278 | 289.0720 | 271.0620; 245.0825 | ||
|
| 4.35 | Procyanidin C1 | C45H38O18 | 281 | 865.1986 | 847.1882; 739.1667; 695.1407; 577.1353 | [865 → 577] 289 |
| 4.51 | Rutoside | C27H30O16 | 355 | 609.1460 | |||
|
| 4.60 | Nicotiflorin | C27H30O15 | 343 | 593.1514 | 285.0403 | 255; 227; 151 |
* confirmed by analytical standard injection.
Figure 2Fideloside (3) MS/MSn fragmentation.
1D and 2D 1H/13C NMR data of Fideloside (3) in DMSO-d6 as solvent.
| Nr. | δ c | DEPT | δ H (J in Hz) | 1H-1H COSY | NOESY | HMBC |
|---|---|---|---|---|---|---|
| 2 | 82.1 | CH | 5.02 (d, 11.02) | H-3 | H-3-; H-6′; H-2′ | H-2′;H-6′; OH-3 |
| 3 | 72.1 | CH | 4.25 (m) | H-2; OH-3 | H-2′, H-6′; OH-3 | OH-3; H-2 |
| 4 | 197.9 | C | H-2; H-6;OH-3 | |||
| 5 | 162.1 | C | H-6; OH-5 | |||
| 6 | 95.6 | CH | 6.04 (s) | OH-5 | ||
| 7 | 165.7 | C | H-6; H-1″ | |||
| 8 | 105.5 | C | H-6; H-1″-H; H-2″ | |||
| 9 | 161.4 | C | H-2; H-1″ | |||
| 10 | 100.5 | C | H-6; OH-5 | |||
| 1′ | 128.4 | C | H-2; H-5′; H-2′ | |||
| 2′ | 115.0 | CH | 6.94 (brs) | H-6′ | H-3; H-2 | H-2; H-5′ |
| 3′ | 144.6 | C | H-5′ | |||
| 4′ | 145.1 | C | H-2′; H-6′ | |||
| 5′ | 115.0 | CH | 6.73 (d, 8.09) | H-6′ | H-6′ | H-2′; H-6′ |
| 6′ | 118.3 | CH | 6.84 (brd, 8.09) | H-2′; H-5′ | H-2; H-5′; H-3 | H-2′; H-2 |
| 1″ | 73.0 | CH | 4.45 (d, 9.63) | H-2″ | H-3″ | H-2″; H-6 |
| 2″ | 70.2 | CH | 3.82 (brt, 9.53) | H-1″; H-3″, OH-2″ | H-4″; H-3″; H-1″ | H-1″ |
| 3″ | 78.6 | CH | 3.11 (m) | H-2″; H-4″; OH-3″ | H-1″; H-2″ | H-1″; H-2″ |
| 4″ | 70.4 | CH | 2.95 (br) | H-3″; H-5″; OH-4″ | H-2″; OH-4; H2-6″ | H-5″; H-3″; H-1″ |
| 5″ | 81.3 | CH | 3.09 (m) | H-6″ | H-2″; Hb-6″ | H-1″ |
| 6″ | 61.7 | CH2 | Ha: 3.70 (m) | H-5″; H-6″; OH-6″ | H-6″; H-4″ | |
| 3-OH | 5.82(d, 6.13) | H-3 | H-3 | |||
| 5-OH | 12.01(s) | H-6 | ||||
| 7-OH | - | |||||
| 3′-OH | 8.87 (brs) | H-2′ | ||||
| 4″-OH | 9.00 (brs) | H-5′ | ||||
| 2″-OH | 4.62 (brs) | H-2″ | ||||
| 3″-OH | 4.83 (brs) | H-3″ | H-2″, H-4″ | |||
| 4″-OH | 4.84 (brs) | H-4″ | ||||
| 6″-OH | 4.57 (brs) | H2-6″ |
Figure 3Fideloside (3) chemical structure with selected key NMR correlations.
Figure 4Left: comparison of experimental CD spectrum (black line) with Boltzmann weighted calculated CD spectrum for the (2R,3R)-enantiomer of compound 3 with a similarity factor S = 0.7099 for sigma = 0.3 eV and 18 nm shift. Right: calculated most stable conformation of the (2R,3R)-enantiomer.
Results of DFT calculations for the (2R,3R) enantiomer of compound 3.
| Conformation | O-C2-C1′-C2′ (in°) | C2′-C3′-O-H (in°) | Energy (kcal/mol) | Boltzmann Weight | CD-Fit |
|---|---|---|---|---|---|
| 1 | −61.8 | −179.5 | 0 | 59.4 | 0.6757 |
| 2 | 122.8 | 2.4 | 0.66 | 19.5 | 0.5712 |
| 3 | −54.7 | 1.0 | 0.97 | 11.5 | 0.7065 |
| 4 | 121.9 | −179.0 | 1.08 | 9.6 | 0.5974 |
| Boltzmann |
|
Figure 5Anti-inflammatory capacity of extracts (3 µg/mL) and isolated Fideloside (1 µM) from Phyllanthus orbicularis. Levels of pro- and anti-inflammatory cytokines after poly-IC stimuli (CTRL+, 100%) of human monocytes.